Exact Imaging Expands U.S. Commercial Presence for ExactVu, its Micro-Ultrasound System for Prostate Cancer Diagnosis
Restructuring Commercial Operations to Penetrate the U.S. Prostate Cancer Diagnosis Market
Exact Imaging, a Canadian medical device company, is significantly strengthening its U.S. commercial team to accelerate the adoption of its 29MHz high-resolution micro-ultrasound system. As part of this expansion, Tim Heyer has been promoted to VP of North American Sales, and the company is reorganizing its sales teams in the Eastern and Midwestern regions. This strategic move aims to maximize the prescription and adoption rates of the device in clinical settings, moving beyond the technology development phase. The company plans to deploy additional sales professionals in key U.S. regions by the end of the year, solidifying its direct sales channel.
Clinical Differentiation and FDA Regulatory History of 29MHz Micro-Ultrasound Technology
The ExactVu system, the core device in this commercialization effort, boasts a resolution approximately 300% higher than conventional 6-9MHz low-resolution ultrasound, enabling the detection of subtle lesions in prostate tissue. It received FDA 510(k) clearance in December 2016, and in 2018, the FusionVu feature, which integrates with MRI, also received approval. This high-resolution technology enables precise diagnosis, significantly reducing the number of unnecessary biopsies. This provides clinical benefits by minimizing patient discomfort and side effects during the diagnostic process and supporting faster decision-making for healthcare providers.
Reshaping Market Competition Through Commercialization of Proprietary Diagnostic Technology
The current prostate cancer diagnosis market is dominated by high-cost multi-parametric MRI (mpMRI) and fusion imaging devices that combine mpMRI with conventional transrectal ultrasound (TRUS). In response, Exact Imaging is targeting a niche market with its micro-ultrasound solution, which offers both cost-effectiveness and precision compared to fusion diagnostic devices from competitors such as Profound Medical and KOELIS. If this technology establishes itself as a new standard protocol in the $1 billion prostate cancer imaging market, it has the potential to rapidly replace existing diagnostic methods. Therefore, this expansion of the U.S. sales team can be seen as an essential step in securing early market share.
Significance of Commercial Execution Strategy Linked to Recent Investment
Exact Imaging's aggressive expansion of its sales organization is closely linked to its successful $10 million Series A funding round led by iGan Partners in February 2026. Building on this capital injection, the company is transitioning from a research and development-focused venture to a commercial execution phase, aiming to generate substantial revenue. Beyond creating innovative devices, it is crucial to establish strong networks with urologists across the country to drive the actual adoption of the device in clinical practice, which is essential for long-term growth. This sales team reorganization, following the capital infusion, demonstrates a well-defined growth path aimed at accelerating revenue and re-evaluating the company's value.
Based on the $10 million in funding secured in February 2026, the establishment of a U.S. direct sales network is expected to rapidly improve the market penetration rate of the ExactVu micro-ultrasound system, which has already received FDA 510(k) clearance. In the $1.08 billion global prostate cancer imaging equipment market, the company aims to expand its market share in the medium to long term by leveraging its superior resolution and high cost-effectiveness compared to existing mpMRI-TRUS fusion competitors such as Profound Medical and KOELIS. Given the nature of the medtech industry, where networks with urologists are key to product adoption, the appointment of a veteran in urology sales as VP is expected to be a practical catalyst for shortening the hospital's purchasing decision-making process. If the standard protocol for prostate biopsy shifts from low-resolution ultrasound to micro-ultrasound, a virtuous cycle of growth is expected to begin, with both device sales and high-margin consumable sales (such as probes) increasing.